Cell or Molecular Dysfunction – Page 2

Actionable Insights Powered by AI

Cell or Molecular Dysfunction
Disease or Syndrome
ENTITY

Anavex’s New Analysis of Alzheimer’s Pill Shows Mixed Results

9 months ago talkbio0Tagged Alzheimer 's disease, amyloid-beta, Anavex, Blarcamesine, Cerebral atrophy, EMA Approval, Mental deterioration, Nerve Degeneration, Phase IIb/III trial, Treatment Effectiveness

Anavex, Alzheimer’s disease, blarcamesine, Phase IIb/III trial, clinical efficacy, neurodegeneration, cognitive decline, amyloid-beta, brain atrophy, EMA approval.

Cell or Molecular Dysfunction
ENTITY
Functional Concept

Amarin Names New CEO Aaron Berg Following Patrick Holt’s Resignation

11 months ago talkbio0Tagged Aaron Berg, Amarin, CEO, Holt, Leadership, Patrick, resignation, Transition Mutation

Amarin, CEO, Patrick Holt, Aaron Berg, Resignation, Leadership Transition

Cell or Molecular Dysfunction
DATE
ENTITY

AbbVie CEO Gonzalez to Step Down, Robert Michael named Successor in Seamless Transition

1 year ago talkbio0Tagged AbbVie's, company's, Gonzalez, Transition Mutation

Gonzalez, AbbVie’s, company’s, Transition Mutation